The 3rd U.S. Circuit Court of Appeals has tossed out a Delaware pharmaceutical company’s antitrust suit in which it claimed Pennsylvania and Tennessee drugmakers conspired to drive up the price of generic versions of brand-name muscle relaxant Skelaxin.

The appeals court affirmed U.S. District Court for the Eastern District of Pennsylvania Judge Cynthia M. Rufe’s ruling, in which she had dismissed the suit for lack of standing.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]